发明名称 |
BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS |
摘要 |
The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-IR kinase inhibitor that inhibits both IGF-IR and IR kinases. Methods are provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-IR kinase inhibitor that inhibits both IGF-IR and IR kinases. Methods are also provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-IR kinase inhibitor that inhibits both IGF-IR and IR kinases, but who would likely not respond to therapy with an anti-IGF-lR antibody. Methods are also provided for identifying patients with cancer who are more likely to benefit from treatment with anti-IGF-lR antibody. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate these methods are also provided.
|
申请公布号 |
CA2783656(A1) |
申请公布日期 |
2011.09.09 |
申请号 |
CA20112783656 |
申请日期 |
2011.03.03 |
申请人 |
OSI PHARMACEUTICALS, LLC |
发明人 |
BUCK, ELIZABETH A.;EPSTEIN, DAVID M.;MIGLARESE, MARK R. |
分类号 |
G01N33/574 |
主分类号 |
G01N33/574 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|